Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2021]

Non-TBI conditioning achieves 76% 2-year EFS in MRD-negative CAYA B-ALL...

Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA

Non-TBI conditioning achieves 76% 2-year EFS in MRD-negative CAYA B-ALL undergoing allogeneic HCT ( Prof Hisham Abdel-Azim - Loma Linda University, Loma Linda, USA )

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL: SWOG 1318 long-te ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL: E1910 phase III trial results ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to...

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of...

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential...

Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia ( Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France )

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in...

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )

Rusfertide provides durable control of haematocrit and phlebotomy reduction in...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses...

Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia

$Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma ( Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia )$

More from ecancer